Apogee Therapeutics, Inc. Common Stock (APGE NASDAQ) stock market data APIs
$84.0215
-5.11(-6.1%)
as of June 3, 2026
Try our APIs with
free plan!
Apogee Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Prev. Close
84.0215
Open
78.9127
High
85.8888
Low
78.8365
52 wk Range
34.34-95.315
Market Cap
5 934 M
Shares Outstanding
61 903 K
EPS
-1.06
Beta
0.692
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Apogee Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Apogee Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Apogee Therapeutics, Inc. Common Stock Fundamental Data
Apogee Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -303 652 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Apogee Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-18
- EPS/Forecast: -1.1313
Get Apogee Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apogee Therapeutics, Inc. Common Stock News
New
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 2 APEX Results For Zumilokibart
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Apogee Therapeutics (APGE) is in focus after reporting stat...
Apogee Therapeutics to Participate in Upcoming June Conferences
Apogee Therapeutics SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following i...
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic...
Wedbush Reaffirms Apogee Therapeutics At Outperform; Lifts Price Target To $135
(RTTNews) - Wedbush reiterated an Outperform rating on Apogee Therapeutics, Inc. (APGE), a clinical-stage biotechnology company, and raised the twelve-month price target to $135 from $120. Analyst Da...
Get Apogee Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
